BRIEF published on 11/25/2025 at 18:38, 11 months 16 days ago ABIONYX Pharma publie ses prévisions d'activité pour le troisième trimestre 2025 Mise À Jour Financière Revenu ABIONYX Pharma 3e Trimestre 2025 Recherche Sur La Septicémie
PRESS RELEASE published on 11/25/2025 at 18:33, 11 months 16 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 11 months 16 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
BRIEF published on 11/12/2025 at 07:05, 1 year ago ABIONYX Pharma en discussions avancées avec l'IHU SEPSIS Partenariat Stratégique ABIONYX Pharma Sepsis IHU SEPSIS Biomédicaments
BRIEF published on 11/12/2025 at 07:05, 1 year ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
PRESS RELEASE published on 11/12/2025 at 07:00, 1 year ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions stratégiques avancées avec l’IHU SEPSIS, 1er centre mondial dédié au sepsis, pour une alliance structurante et transformante dans le traitement global du sepsis Alliance ABIONYX Pharma Sepsis Discussions Stratégiques IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 1 year ago Validation génétique de l'ApoA-I dans le sepsis par ABIONYX Pharma ABIONYX Pharma Thérapies Innovantes Apolipoprotéine A-I Septicémie Validation Génétique
BRIEF published on 10/21/2025 at 18:54, 1 year ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 1 year ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce une validation historique dans la revue NATURE confirmant la causalité génétique de l'apolipoprotéine A-I (ApoA-I) dans le sepsis. Une avancée majeure dans le traitement de la septicémie Validation Historique ABIONYX Pharma Nature Septicémie Causalité Génétique
PRESS RELEASE published on 10/21/2025 at 18:49, 1 year ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
Published on 11/12/2026 at 14:31, 1 hour 21 minutes ago First Breach Inc. Announces Third Quarter 2026 Earnings Conference Call
Published on 11/12/2026 at 14:00, 1 hour 52 minutes ago GameSquare Announces Peaky Blinders Digital Fan Experience, Advancing the Company's IP Monetization Strategy
Published on 11/12/2026 at 14:00, 1 hour 52 minutes ago NuRAN Wireless Highlights Recurring Revenue Economics and Growth Potential of Its 5,092-Tower Contracted NaaS Portfolio
Published on 11/12/2026 at 13:45, 2 hours 7 minutes ago Amarc and Freeport Successfully Complete 2026 Joy Copper-Gold District Exploration Program
Published on 11/12/2026 at 13:30, 2 hours 22 minutes ago Nextech3D.ai to Present at the Small Cap Growth Virtual Investor Conference November 18th at 12:30 p.m. ET
Published on 11/12/2026 at 15:30, 22 minutes ago Iute Group Reports Unaudited 9M 2026 Results on 25 November 2026 – Invitation to Earnings Webcast/Call on the Same Day
Published on 11/12/2026 at 15:30, 22 minutes ago Highlight Group publishes results for the first nine months of 2026
Published on 11/12/2026 at 15:09, 42 minutes ago EQS-Adhoc: Starcom Holding AD: Payment under Corporate Bonds
Published on 11/12/2026 at 15:00, 51 minutes ago Clemta Expands Partner API to Power End-to-End U.S. Business Services
Published on 11/12/2026 at 08:56, 6 hours 55 minutes ago Number of shares and voting rights - October 2026 (In French only)
Published on 11/12/2026 at 08:56, 6 hours 55 minutes ago Nombre total d'actions et droits de vote - octobre 2026
Published on 11/12/2026 at 08:40, 7 hours 12 minutes ago FREY forms a €400 million equity partnership with GIC to invest in premium European retail parks
Published on 11/12/2026 at 08:40, 7 hours 12 minutes ago FREY et GIC s’associent pour investir 400 M€ de capital dans les retail parks premium en Europe
Published on 11/10/2026 at 18:00, 1 day 21 hours ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
